Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.

·3 min read
Merck Sales Beat Estimates, But the Stock Is Falling. Here’s 1 Reason to Be Bullish.

Strong revenue from cancer treatment Keytruda stood out in Merck's results, with analysts highlighting upside to sales estimates for the drug.